Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesTransplantAetna Transplant Immune Cell Assays Coverage Updat…
    Ask Trek AI about this page

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    CurrentAetnaPolicy 0773

    Transplant Immune Cell Function Assays

    Customize your policy alerts

    Sign up for Aetna Policy 0773 alerts

    Get alerted when Policy 0773 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Defines Aetna's coverage stance for immune cell function assays used in transplant recipients, including when the ImmuKnow Assay is considered medically necessary and which assays/indications are experimental or investigational. Affects clinicians ordering or adjudicating such assays for transplant patients.

    Policy Summary
    PayerAetna
    PolicyTransplant Immune Cell Function Assays
    Policy CodePolicy 0773
    Change TypeNo material change
    Effective DateJan 9, 2009
    Last ReviewOct 26, 2023
    Next Review DateAug 22, 2024
    Key ActionObtain prior authorization and document assay type, timing, quantitative results and intended management when ImmuKnow or other immune function assays are used to guide immunosuppression or prophylaxis decisions.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    ImmuKnowcovered indication
    Multiple assaysexperimental/investigational
    0.43pooled sensitivity - rejection
    0.58pooled sensitivity - infection
    510(k) 2002FDA status (ImmuKnow)

    Coverage Criteria for Immune Cell Function Assays

    ImmuKnow Assay — Medical Necessity

    Covered when ALL of the following are met

    ImmuKnow - covered indication: Use of the ImmuKnow Assay (Transplantation Immune Cell Function Assay, Cylex) is considered medically necessary to adjudicate over-immunosuppression in subpopulations of transplant recipients with co-morbid infection or cancer.

    Per Aetna 'Medical Necessity' statement.

    Experimental / Investigational

    Not covered / Experimental and investigational for these indications

    ImmuKnow - not covered indications: ImmuKnow Assay is considered experimental/investigational for all other indications including: CMV risk stratification in lung transplant recipients; detection of cellular immune function in renal cell carcinoma; identification of individuals at risk for rejection prior to kidney, liver, lung, or other solid organ transplant; management during allogeneic hematopoietic stem cell transplantation; management of inflammatory bowel disease; management of organ transplant rejection post solid organ transplant; monitoring the immune response following surgery; prediction of infection risk with disease-modifying anti-rheumatic drugs; and prediction of infection risk in lupus nephritis.
    Policy Summary
    PayerAetna
    PolicyTransplant Immune Cell Function Assays
    Policy CodePolicy 0773
    Change TypeNo material change
    Effective DateJan 9, 2009
    Last ReviewOct 26, 2023
    Next Review DateAug 22, 2024
    Key ActionObtain prior authorization and document assay type, timing, quantitative results and intended management when ImmuKnow or other immune function assays are used to guide immunosuppression or prophylaxis decisions.
    SourceLink
    On This Page
    Coverage Criteria for Immune Cell Function AssaysCoding and Test ThresholdsProvider Actions, Authorization, and DocumentationCandidate Assays and Transplant-Specific ThresholdsEvaluation and Monitoring RequirementsLaboratory and Center RequirementsPost-Transplant Use and MonitoringBackground and DefinitionsPolicy Revision History

    Enumerated in policy.

    Other assays - experimental/investigational: The following assays/interventions are considered experimental/investigational because clinical value has not been established: Pleximmune test for prediction of acute cellular rejection in pediatric liver/intestine transplant; T-SPOT.CMV; IFN-γ ELISpot assays (e.g., T-Track CMV); QuantiFERON-CMV for certain indications; the CMV T Cell Immunity Panel; measurement of donor-derived cell-free DNA (e.g., Viracor TRAC) for allograft rejection; and gamma interferon response measurement for lung transplantation.

    Enumerated in policy.

    Infection risk performance

    Summary of evidence-based performance characteristics from cited analyses and studies

    Infection risk identification: Pooled evidence indicates limited-to-moderate ability of the ImmuKnow (CICFA) assay to identify patients at increased risk for infection post-transplant (pooled sensitivity approximately 0.58; pooled specificity approximately 0.69), with heterogeneity across studies and some organ-specific supportive findings.as reported

    Meta-analyses and systematic reviews report pooled estimates and study heterogeneity.

    Rejection risk performance

    Evidence on rejection detection

    Rejection risk identification: Pooled evidence demonstrates poor sensitivity of ImmuKnow for identifying rejection (pooled sensitivity approximately 0.43) and substantial heterogeneity; many individual studies did not show consistent associations between single ImmuKnow values and subsequent rejection events.as reported

    Meta-analyses and cohort studies report limited performance for rejection detection.

    Use considerations

    Contextual recommendations from investigators

    Serial monitoring vs single time-point: Investigators commonly state that isolated single ImmuKnow values lack sufficient diagnostic capacity; serial, individualized monitoring over time may be more informative for guiding immunosuppression management and detecting trends associated with infection or clinical stability.n/a

    Authors call for prospective longitudinal outcome studies to establish clinical utility.

    Evidence summaries and proposed utility

    Assay-specific evidence statements and contexts from the provided text:

    ImmuKnow - mixed evidence: Published studies report heterogeneous ImmuKnow findings: some cohorts and meta-analyses associate lower ATP with increased infection risk (e.g., De Paolis; lupus/DMARD cohorts), while many pediatric and adult transplant series show inconsistent discrimination for rejection or infection; a randomized trial (Ravaioli et al.) reported improved 1-year survival and fewer infections when tacrolimus dosing was adjusted by serial ImmuKnow testing using predefined ATP thresholds.examples reported in studies (e.g., ATP <130 ng/ml and >450 ng/ml used to guide tacrolimus adjustments in Ravaioli et al.)

    Evidence ranges from negative/neutral to promising in small RCTs; overall heterogeneity limits broad recommendations.

    Pleximmune - preliminary validation: Pleximmune measures donor-specific CD154+ cytotoxic memory T cells and reported sensitivity/specificity near 84%/80% in pediatric liver/intestine training/validation cohorts (n=214) with derived IR thresholds; however, authors note small sample sizes, wide confidence intervals, and absence of clinical outcome studies supporting routine use.IR >=1.1 post-transplant; IR >=1.23 pre-transplant

    FDA HDE status but limited clinical utility evidence.

    T-SPOT.CMV and ELISPOT assays: T-SPOT.CMV and other IFN-γ ELISpot assays measure CMV-specific T-cell responses (pp65, IE-1); observational studies suggest higher antigen-specific responses associate with lower subsequent viremia/reactivation in some cohorts, but these are laboratory-developed or not FDA-cleared tests and performance varies by antigen and assay platform.study-specific spot-count thresholds reported in some analyses

    Assay-specific validation and lack of FDA clearance limit generalizability.

    Graft-derived cell-free DNA (GcfDNA): Quantitative GcfDNA monitoring shows promise as a noninvasive biomarker for early detection of rejection in kidney and heart transplant studies, with rejection episodes accompanied by substantial increases in graft-derived cfDNA (examples reported >5% during rejection versus <0.5% baseline post-engraftment).>5% suggests rejection

    Promising surveillance tool but clinical utility studies still emerging.

    Contextual clinical criteria

    Assay use described as reasonable when intended to risk-stratify immunocompromised patients or to guide prophylaxis/monitoring decisions in transplant or high-immunosuppression settings, provided timing and assay type are appropriate.

    Context requirements: Assay use is reasonable when performed in transplant or other immunocompromised patients to assess CMV-specific or global cellular immunity with the explicit intent to inform risk stratification, duration of antiviral prophylaxis, or surveillance frequency; testing should be performed at specified time points relative to transplant or prophylaxis (for example day +28 and +100 after allo-HSCT, or around planned prophylaxis cessation in SOT) and accompanied by documentation of assay type and quantitative thresholds used.

    Guidelines and cohort studies support assay-specific timing and interpretation; assays are not interchangeable and require assay-specific validation.

    Examples of codes identified in the policy as not covered for indications listed in the CPB include CPT/HCPCS codes used for cellular function and proprietary transplant tests such as 86352 (cellular function assay), 0118U (donor-derived cell-free DNA quantification), 81560 (Pleximmune/CD154+ TcM algorithm), and assay descriptors such as IFN-947 (ELISpot/T-Track CMV). The policy also lists numerous ICD-10 diagnosis codes that, when submitted for excluded indications, may lead to denial (examples include codes for complications of transplanted organs, specific transplant status codes, CMV disease, PTLD, inflammatory bowel disease, and lupus nephritis).

    Providers should verify coding and clinical indication prior to submission because claims for CPT/HCPCS/ICD-10 codes listed as “not covered for indications listed in the CPB” may be denied when submitted with excluded diagnoses or for experimental/ investigational indications.

    The policy states there is insufficient evidence to support use of the ImmuKnow Assay for management of organ transplant rejection or for identifying individuals at risk for rejection prior to solid organ transplant; Aetna considers these indications experimental/investigational because clinical effectiveness has not been established.

    Akimoto et al (2013) and other reviewers cited in the policy emphasize the need for prospective clinical outcome studies to determine ImmuKnow's role in managing transplant recipients, and the policy notes this insufficiency may lead to denial when the assay is requested for rejection-risk management or pre-transplant risk stratification.

    Although Pleximmune (donor-specific CD154+ cytotoxic memory T cells) showed correlation with acute cellular rejection in pediatric liver/intestine cohorts, the policy notes there are no clinical outcome studies demonstrating clinical utility and that sensitivity/specificity estimates derive from small sample sets with wide confidence intervals.

    Because routine clinical benefit has not been established, the policy describes the Pleximmune test as experimental/investigational for prediction of acute cellular rejection and other indications.

    The policy highlights that some commercial CMV immune panels (for example, the CMV T Cell Immunity Panel described by the vendor) have not been cleared or approved by the FDA for diagnostic use.

    The absence of FDA clearance or approval for certain assays is noted as a factor that may influence payer coverage decisions and prior authorization requirements for those laboratory-developed or non–FDA-cleared tests.

    The document emphasizes that assay results are assay-specific and not interchangeable across platforms: for example, T-SPOT.CMV and QuantiFERON-CMV demonstrated only moderate agreement (especially by day +100 post–allo-HSCT), and the authors conclude that future guidance should be assay-specific.

    Because concordance between different CMV immune assays is incomplete, the policy advises against substituting results from one platform for another without validation and appropriate context.

    Sections of the document include literature summaries and full reference listings supporting the background and evidence review; these chunks provide bibliographic citations rather than prescriptive coverage criteria.

    The references cited (for example, meta-analyses, cohort studies, and device summaries) underpin the policy conclusions about assay performance, regulatory status, and evidence gaps but do not themselves state additional coverage rules.

    The policy specifies that the assays discussed (including ImmuKnow, Pleximmune, T-SPOT.CMV, QuantiFERON-CMV, CMV T Cell Immunity Panel, IFN-γ ELISpot tests, and donor-derived cell-free DNA assays) are not supported for most indications beyond adjudicating over‑immunosuppression in transplant recipients with co‑morbid infection or cancer, and are therefore considered experimental or investigational for those other clinical uses.

    Use of these assays for indications outside the narrowly defined medically necessary purpose is listed in the policy’s experimental/investigational section and should not be relied upon for routine clinical decision-making.

    Pooled evidence and the policy explicitly indicate that using CICFA/ImmuKnow solely to predict rejection or as a definitive diagnostic for rejection is not supported; meta-analysis data show poor pooled sensitivity for rejection and inconsistent findings across studies.

    Consequently, the policy characterizes ImmuKnow as not medically necessary/experimental when requested for prediction or definitive diagnosis of rejection rather than for adjudicating over‑immunosuppression in selected transplant subpopulations.

    Multiple pediatric cohort studies cited in the policy reported that ICFA/ImmuKnow did not reliably discriminate between rejection, infection, or immunologic stability in pediatric heart and renal transplant populations, indicating limited utility in those settings.

    A study in patients with renal cell carcinoma found no clinical significance of ImmuKnow ATP levels for prognosis, further supporting the policy’s conclusion that ImmuKnow has unreliable performance in several pediatric and non-transplant cohorts.

    For CMV-specific risk stratification in lung transplant recipients, the policy notes limited and non‑definitive evidence: a cited trial found trends suggesting ImmuKnow might help individualize prophylaxis length, but differences did not reach statistical significance and sample sizes were small.

    Accordingly, the policy lists ImmuKnow use for CMV risk stratification in lung transplant recipients as experimental/investigational pending confirmatory studies.

    Coding and Test Thresholds

    Covered CPT Codes (if selection criteria are met)CPTCovered
    86352Cellular function assay involving stimulation (eg, mitogen or antigen) and detection of biomarker (EG, ATP).
    Other CPT/HCPCS/Proprietary codes referencedmixed
    0118UTransplantation medicine, quantification of donor-derived cell-free DNA using whole genome next-generation sequencing, plasma, reported as percentage of donor-derived cell-free DNA in the total cell-free DNA.
    81560Transplantation medicine (allograft rejection, pediatric liver and small bowel), measurement of donor and third-party-induced CD154+T-cytotoxic memory cells, utilizing whole peripheral blood, algorithm reported as a rejection risk score.
    IFN-947ELISpot assay (e.g., T-Track CMV)– no specific code.
    ICD-10 codes referenced (covered or not covered lists)ICD-10
    A00.0 - B99.9Infectious and parasitic diseases.
    C00.0 - D09.9Malignant neoplasms.
    T45.1X5+Adverse effect of antineoplastic and immunosuppressive drugs.
    B25.8Other cytomegaloviral diseases.
    K50.00 - K50.019Crohn's disease.
    K51.00 - K51.919Ulcerative colitis.
    M32.14Glomerular disease in systemic lupus erythematosus.
    Z76.82Awaiting organ transplant status.
    Z94.0 - Z94.9Transplanted organ and tissue status.
    No explicit CPT/HCPCS/ICD codes in this segmentmixed
    No codes listed
    ATP threshold for HCC recurrence prediction — example threshold
    ATP threshold (HCC recurrence prediction)175 ng/ml
    Source study populationLiver transplant recipients with HCC (Cheng et al. cohort)
    Associated outcomeATP <=175 ng/ml associated with higher risk of post-transplant HCC recurrence
    Manufacturer suggested ranges referenced in studies
    Manufacturer suggested ImmuKnow rangesLow: <=225 ng/ml; Normal: 226–524 ng/ml; High: >=525 ng/ml
    ContextRanges referenced across multiple clinical studies and used to categorize immune status
    Note on variabilityThresholds and interpretation vary by study population and timing post-transplant
    ImmuKnow ATP threshold for infection in lupus nephritis
    ImmuKnow infection threshold (lupus nephritis)<=300 ng/ml predicts severe infection
    PerformanceSensitivity 77%, Specificity 77%
    Study populationPatients with lupus nephritis receiving immunosuppressive therapy
    ImmuKnow adjustment thresholds used in Ravaioli et al.
    Tacrolimus adjustment thresholds (Ravaioli et al.)If ATP <130 ng/ml → reduce tacrolimus dose by 25%; if ATP >450 ng/ml → increase tacrolimus dose by 25%
    Monitoring scheduleSerial ImmuKnow testing before transplant, immediately post-op, day 1, weeks 1–4, 6, 8, and months 3,6,9,12
    Reported clinical effectIntervention arm had higher 1‑year survival (95% vs 82%) and fewer prolonged infections
    Pleximmune IR thresholds
    Pleximmune post-transplant IR thresholdIR >= 1.1 predictive of rejection within 60 days (reported)
    Pleximmune pre-transplant IR thresholdIR >= 1.23 predictive of subsequent rejection (reported)
    Performance (training/validation)Reported sensitivity ~84% and specificity ~80% in pediatric LTx/ITx cohorts
    GcfDNA rejection signal — >5% rejection signal vs <0.5% after engraftment
    GcfDNA rejection signal (example)>5% graft-derived cfDNA observed during rejection vs <0.5% after early post-engraftment decline
    Temporal patternGcfDNA rises often precede clinical or biochemical signs of rejection
    UtilityNoninvasive biomarker potentially useful for early detection of rejection
    Reported dd-cfDNA thresholds and performance (examples from literature)
    Example dd‑cfDNA thresholds (kidney/heart)>1% (pre-specified SNP‑based kidney assay); >=0.74% (AMR detection in one study); 0.2% (heart transplant surveillance threshold with 44% sensitivity, 97% NPV)
    Alternative units reportedThresholds also reported as copies/ml (e.g., 52 cp/ml) or fraction (%) depending on assay
    Performance notesReported AUCs and sensitivities vary by organ and assay (e.g., AUC 0.87 for SNP-based kidney assay)
    QuantiFERON-CMV reactive threshold
    QuantiFERON-CMV reactive threshold>= 0.2 IU/mL (reactive)
    Indeterminate result rateIndeterminate results occurred (e.g., 3.4% in one lung transplant study) and were excluded from analysis
    Clinical contextUsed to assess CMV-specific CD8+/CD4+ responses for risk stratification in neonates, HSCT, autoimmune and transplant populations
    Immuknow ATP categories — Low/Intermediate/High
    ImmuKnow ATP categories (example)Low: <225 ng/mL; Intermediate: 225–525 ng/mL; High: >=525 ng/mL
    Use in studiesCategories used to stratify immunosuppression intensity and correlate with infection/rejection outcomes
    Note on variabilityExact cutoffs and interpretation may vary across studies and populations
    CMV DNAemia threshold used in autoimmune study
    CMV DNAemia threshold (autoimmune study)> 3 log10 IU/mL considered clinically significant CMV infection
    Study populationPatients with active systemic lupus erythematosus receiving immunosuppressive therapy
    Relation to immune assayQuantiFERON-CMV status post-immunosuppression associated with subsequent clinically significant CMV infection
    CMV DNAemia threshold for significant infection in lung transplant study
    CMV DNAemia threshold (lung transplant study)> 1,000 copies/mL considered significant CMV infection/disease
    Study contextDefined threshold used in prospective lung transplant cohort assessing Immuknow and QuantiFERON-CMV around prophylaxis cessation
    Outcome frequencyIn that cohort, 21.7% of patients developed significant CMV infection/disease

    Provider Actions, Authorization, and Documentation

    Prior Authorization

    Prior authorization and coding verification — confirm CPT/ICD match policy (e.g., 86352)

    Verify that the procedure and diagnosis codes submitted match the policy guidance (example covered code: CPT 86352 for cellular function assay). Confirm coverage criteria are met before ordering and billing; obtain prior authorization when payer rules require it for the covered indication.

    • Covered CPT example: 86352 (cellular function assay involving stimulation and detection of biomarker such as ATP).
    • Verify applicable ICD-10 diagnosis supports the intended indication (policy lists covered and not-covered diagnosis groups).
    • Obtain prior authorization when required by payer rules for the covered indication.
    Prior Authorization

    Prior authorization recommended — due to inconsistent/insufficient evidence

    Consider prior authorization for clinical use because evidence is inconsistent and insufficient to support many assay-directed management decisions; document the clinical rationale when requesting authorization.

    • Policy states pooled evidence is limited for infection and poor for rejection identification, supporting prior authorization for clinical use when assay results will influence management.
    • Provide clinical justification and supporting documentation when seeking authorization.
    Prior Authorization

    Prior authorization when used to adjust immunosuppression — include assay values and plan

    If assay results will be used to adjust immunosuppression, obtain prior authorization and include the assay values and the planned management changes in the authorization request.

    • One RCT used ImmuKnow-directed tacrolimus adjustments (reduce 25% if ATP <130 ng/mL; increase 25% if ATP >450 ng/mL) and recorded management decisions tied to assay values.
    • Policy advises providing assay values and intended management plan when prior authorization is sought for therapy adjustments.
    Prior Authorization

    Prior authorization likely required for non‑FDA-cleared assays

    Expect prior authorization or additional documentation for assays that are not FDA-cleared; provide clinical justification and lab accreditation information when requesting coverage.

    • Policy notes some commercial panels (e.g., CMV T Cell Immunity Panel) have not been FDA-cleared and may require payer review.
    • Indicate that high-complexity laboratory tests are performed in CLIA/CAP-accredited labs when relevant.
    Prior Authorization

    Prior authorization for post‑transplant immune monitoring — document transplant status and timing

    When ordering assays for post‑transplant immune monitoring (risk stratification or prophylaxis decisions), include transplant status, timing relative to transplant, and intended use in the prior authorization or clinical documentation.

    • Policy describes assay use at specific post-transplant time points (e.g., day +28 and +100 post-allo-HSCT; months 3, 6, 8, 10, 12 post-lung transplant) to guide prophylaxis/monitoring.
    • Document transplant type, post-transplant day/month of testing, and whether result will inform prophylaxis duration or surveillance strategy.
    Note

    Prior authorization — policy history contains no explicit requirements

    No explicit prior authorization steps are specified in the policy history or administrative notes; refer to payer-specific prior authorization rules as needed.

    • Policy history and administrative notes do not define provider prior authorization steps.
    Note
    Step Therapy

    Prefer serial monitoring over single time‑point when guiding therapy

    Prefer serial, individualized monitoring rather than relying on a single time‑point assay value when using assays to guide clinical decisions.

    • Multiple authors state isolated ImmuKnow values lack diagnostic capacity and that individual serial monitoring may better inform immunosuppression changes.
    Documentation Required

    Documentation required for therapy changes — baseline and serial assay documentation

    When proposing immunosuppression changes based on assay results, document baseline clinical status and serial assay measurements, and record the rationale and planned dose adjustments.

    • The Ravaioli RCT specified serial testing and predefined tacrolimus dose-change thresholds tied to ATP values; policy recommends stepwise documentation when adjustments are made.
    • Include baseline status, each assay result with dates, and the management decision linked to those results.
    Note

    Step therapy — none specified in policy

    No step therapy rules are provided in this policy section; follow institution and payer protocols for stepwise treatment prior to assay‑directed management.

    • Policy does not define mandatory step therapy algorithms.
    Step Therapy

    Assay‑guided prophylaxis decisions — document results and prophylaxis plan

    Use CMV-specific assays to support individualized antiviral prophylaxis decisions, and document assay results and corresponding changes in prophylaxis duration or surveillance.

    • Studies described use QuantiFERON-CMV and ImmuKnow around prophylaxis cessation (e.g., 6 months post‑lung transplant) to explore individualized discontinuation of prophylaxis.
    • Document assay type, quantitative thresholds used, timing relative to prophylaxis cessation, and planned monitoring of CMV DNAemia.
    Note

    Step therapy — no requirements described

    No step therapy requirements are described in these policy chunks; apply local clinical care pathways and payer rules.

    • Policy text contains no mandated step therapy sequences.
    Documentation Required

    Clinical indication documentation — state purpose is adjudicating over‑immunosuppression

    Document that ImmuKnow is being used to adjudicate potential over‑immunosuppression in transplant recipients with comorbid infection or cancer to meet the medically necessary indication.

    • Policy states ImmuKnow is medically necessary specifically to adjudicate over‑immunosuppression in transplant recipients with co‑morbid infection or cancer.
    • Include the clinical context (infection or cancer) in the request and medical record.
    Documentation Required

    Document timing and serial measurements — record pre/post‑transplant schedule

    Document timing of serial ImmuKnow measurements relative to transplant and clinical events; studies use pre‑transplant and multiple post‑transplant time points (e.g., days 7,14,21,42 and months 3,6,12).

    • De Paolis collected samples pre-transplant and at days 7, 14, 21, 42 and months 3, 6, 12; other studies similarly used serial measurements.
    • Record exact dates of sampling and relationship to suspected infection or rejection.
    Documentation Required

    Assay result reporting — document Pleximmune IR and thresholds used

    Report Pleximmune results as the immunoreactivity index (IR) and include the threshold used (examples reported: IR ≥1.1 post‑transplant; pre‑transplant IR ≥1.23) when presenting results to justify clinical decisions.

    • Pleximmune IR thresholds reported in training/validation: post‑transplant IR ≥1.1 and pre‑transplant IR ≥1.23 predictive for rejection in pediatric LTx/ITx cohorts.
    • Include IR value and whether it meets the specified threshold in clinical documentation.
    Documentation Required

    Supporting documentation from studies — include biopsy pairing/serial dd‑cfDNA when applicable

    When using dd‑cfDNA studies to support a diagnosis of rejection, include paired biopsy results or serial dd‑cfDNA measurements as supporting documentation because many studies correlated dd‑cfDNA with biopsy‑proven rejection.

    • SNP‑based dd‑cfDNA study reported biopsy‑matched samples and used a pre‑specified cut‑off (>1%) to detect active rejection with high AUC.
    • Record biopsy dates/results and corresponding dd‑cfDNA values when available to support interpretation.
    Documentation Required

    Required assay documentation — record assay type, quantitative result and thresholds used

    Providers must document the assay type, the quantitative result and thresholds applied (examples: QuantiFERON‑CMV reactive threshold ≥0.2 IU/mL; ImmuKnow ATP categories: <225, 225–525, ≥525 ng/mL) and timing relative to transplant or prophylaxis.

    • QuantiFERON‑CMV reactive threshold commonly reported as ≥0.2 IU/mL.
    • ImmuKnow ATP category cut‑points: low <225 ng/mL; intermediate 225–525 ng/mL; high ≥525 ng/mL.
    • Document when the sample was taken relative to transplant and any prophylaxis changes.
    Note

    Administrative note — policy history contains no provider authorization steps

    Administrative policy history and notes do not prescribe provider authorization steps; follow the policy content and payer-specific administrative procedures.

    • Policy history and additional information sections record review dates and administrative notes but do not define provider authorization workflow.
    Denial Risk

    Denial triggers — claims with excluded codes/indications may be denied

    Claims submitted with CPT/HCPCS/ICD‑10 codes listed as not covered for CPB indications may be denied if paired with excluded diagnosis codes or for experimental/investigational indications; ensure coding aligns with covered indications.

    • Policy lists CPT/HCPCS codes and multiple ICD‑10 codes as not covered for the CPB‑listed indications (examples: B25.8 for CMV, codes for post‑transplant complications).
    • Avoid submitting claims with excluded diagnosis codes for indications designated as experimental/investigational.
    Denial Risk

    Denial risk — insufficient evidence for rejection‑risk use of ImmuKnow

    Insufficient evidence supports ImmuKnow for management of transplant rejection or for identifying individual pre‑transplant rejection risk; use for those indications may be denied.

    • Policy states there is insufficient evidence of ImmuKnow effectiveness for management of organ transplant rejection and for identifying individuals at risk for rejection prior to transplant.
    • Provide alternative supporting clinical evidence if ordering for rejection‑related indications.
    Denial Risk

    Denial risk — regulatory status of assay may affect coverage

    Regulatory status can affect coverage: tests that are not FDA‑cleared (e.g., T‑SPOT.CMV as a laboratory‑developed test) may not meet payer coverage requirements without additional justification.

    • T‑SPOT.CMV has not been cleared or approved by the FDA and is performed in a CLIA/CAP‑accredited lab.
    • When ordering non‑FDA‑cleared assays, include laboratory accreditation and clinical rationale in authorization requests.
    Prior Authorization

    Authorization considerations — include comprehensive documentation to reduce denial risk

    Because some assays lack explicit authorization language in the policy and may not be FDA‑cleared, include comprehensive clinical documentation to mitigate potential denial risk.

    • Policy notes assays described have not been FDA‑cleared/approved in some cases and that no explicit authorization criteria are stated; thorough documentation may be required by payers.
    Denial Risk

    Denial risk — indeterminate/invalid results affect interpretation and actionability

    Indeterminate QuantiFERON‑CMV results were excluded in analyses and may limit actionability; document indeterminate or invalid results and consider repeat testing or alternative assays before basing management decisions.

    • One study reported 3.4% indeterminate QuantiFERON‑CMV results which were excluded from analyses.
    • Indeterminate/invalid results can affect the interpretability of assay‑guided decisions and potential coverage adjudication.
    Note

    Administrative note — no additional authorization/denial criteria in these sections

    No explicit authorization or denial criteria are present in the remaining administrative portions of the document; follow payer‑specific policies for claim adjudication.

    • Administrative and reference sections do not provide additional authorization or denial criteria.

    Candidate Assays and Transplant-Specific Thresholds

    Pleximmune transplant-specific thresholds

    Pleximmune pre- and post-transplant IR thresholds were derived to predict rejection in pediatric liver and intestine transplant recipients.

    Pleximmune candidate criteria: Use in pediatric liver or intestine transplantation where immunoreactivity index (IR) thresholds are applied to predict rejection: pre-transplant IR >= 1.23 and post-transplant IR >= 1.1 are reported to predict rejection within the 60-day post-sampling period in validation sets.pre >=1.23; post >=1.1

    Derived from training/validation cohorts (total n≈214); limited clinical outcome data and authors note need for further validation.

    GcfDNA monitoring

    Graft-derived cfDNA monitoring context and typical rejection signal levels reported in transplant studies

    GcfDNA monitoring: Serial measurement of graft-derived cell-free DNA (GcfDNA) may detect allograft injury earlier than clinical or biochemical signs; studies report immediate post-engraftment elevations followed by decline to <0.5% and that rejection episodes are associated with marked increases (examples >5% of total cfDNA) preceding clinical detection.>5% indicates possible rejection

    Noninvasive adjunctive monitoring; clinical utility under investigation.

    Transplant-specific assay uses

    Use of CMV-specific immune assays in transplant populations is described in several contexts.

    HSCT CMV monitoring: In allogeneic HSCT, IFN-γ ELISpot (T-SPOT.CMV) and QuantiFERON-CMV have been evaluated at standardized post-transplant time points (e.g., day +28 and +100) to assist CMV risk stratification; studies report high negative predictive value for protection against clinically significant CMV infection at day +100 in small cohorts, but assays showed only moderate agreement and are not interchangeable.QuantiFERON-CMV reactive >=0.2 IU/mL

    Assay-specific validation and timing important; moderate concordance between platforms.

    Lung transplant prophylaxis decisions: In lung transplant recipients, combined assessment with QuantiFERON-CMV and ImmuKnow around prophylaxis cessation (e.g., 6 months post-transplant) has been proposed to individualize duration of antiviral prophylaxis and surveillance; cohort data do not definitively demonstrate superiority and findings were not statistically conclusive in some studies.ImmuKnow categories: low <225; intermediate 225-525; high >=525 ng/ml; QuantiFERON-CMV reactive >=0.2 IU/mL

    Clinicians were blinded to assay results in reported cohort; use remains investigational for routine practice.

    Evaluation and Monitoring Requirements

    Documentation Required

    Monitoring protocols

    Monitoring protocols in published studies typically include a baseline pre-transplant sample and multiple post-transplant samples (examples: days 7, 14, 21, 42 and months 3, 6, 12); document these time points when relevant to interpretation.

    • List exact sampling schedule used and relation to clinical events (e.g., suspected infection or rejection).
    Documentation Required

    When assays guide immunosuppression, serial measurements and documented stepwise adjustments are used

    When assays are used to guide immunosuppression, serial measurements and documentation of pre-specified thresholds and stepwise adjustments are used in studies (for example ImmuKnow-directed tacrolimus changes and Pleximmune risk stratification).

    • Document the thresholds that will trigger each management step and the intended magnitude of adjustment.
    Documentation Required

    dd-cfDNA evaluation context

    dd-cfDNA evaluation has been performed both as surveillance testing and with biopsy-paired samples; interpretation often requires correlation with biopsy and clinical data.

    • If dd-cfDNA is used, provide biopsy results when available or serial dd-cfDNA trends to support clinical conclusions.
    Note
    Note
    Note

    Laboratory and Center Requirements

    Documentation Required

    CENTER REQUIREMENTS — CLIA/CAP lab processing for high-complexity assays

    T-SPOT.CMV is performed in a CLIA- and CAP-accredited laboratory; high-complexity assays should be processed in appropriately accredited centers.

    • Confirm the testing laboratory's CLIA/CAP accreditation when ordering or documenting these assays.

    Post-Transplant Use and Monitoring

    Immune cell function testing (ImmuKnow) — studies evaluate ImmuKnow at various post-transplant times; policy permits use to adjudicate over-immunosuppression in suitable contexts
    Timing variability in studiesImmuKnow evaluated at multiple post‑transplant time points across studies (weeks to years; examples include early post-op through months/years)
    Policy permitted useImmuKnow is considered medically necessary to adjudicate over‑immunosuppression in select transplant recipients with comorbid infection or cancer
    Interpretation cautionStudy heterogeneity and timing affect interpretation; serial measurements are often recommended rather than single time‑points
    ImmuKnow/CICFA testing as adjunct immune monitoring — measurements across broad post-transplant timeframe to assess infection/rejection associations
    Adjunct immune monitoring roleImmuKnow/CICFA used as an adjunct to assess infection/rejection associations across a broad post‑transplant timeframe
    Evidence summaryMany studies show association of lower ATP with infection; evidence for rejection discrimination is inconsistent
    Use recommendationAssay results should be interpreted with clinical context and serial measurements when possible
    ImmuKnow serial testing and tacrolimus dose adjustments — serial testing used to guide immunosuppression adjustments in cited studies
    Serial testing to guide tacrolimus adjustmentsSerial ImmuKnow testing was used to guide 25% tacrolimus dose reductions/increases based on ATP thresholds in the RCT (reduce if <130 ng/ml; increase if >450 ng/ml).
    Reported benefitsRCT reported improved 1-year survival and fewer prolonged infections in the testing-guided arm
    Documentation needWhen used to adjust immunosuppression, serial values and management rationale should be documented
    T-SPOT.CMV ELISPOT monitoring — serial monitoring every 2 weeks post-HCT up to 26 weeks described
    T-SPOT.CMV monitoring schedule (example)Serial monitoring every 2 weeks post‑HCT up to 26 weeks reported in prospective study
    PurposeAssess dynamics of CMV-specific immunity and relation to reactivation risk
    Assay statusPerformed as a CLIA/CAP laboratory test (not FDA-cleared) in cited studies
    CMV-IGRA or immune function assays with documented timing relative to transplant and prophylaxis — specific time points (day +28, +100; months 3,6,8,10,12) referenced
    Documented time points relative to transplant/prophylaxisExamples include day +28 and +100 post‑allo‑HSCT; months 3, 6, 8, 10, 12 post‑lung transplant around prophylaxis cessation
    Clinical intentUsed to risk‑stratify patients for CMV reactivation and to individualize prophylaxis duration or surveillance
    Assay-specific interpretationAssay choice matters; results are not interchangeable across platforms and require assay‑specific thresholds

    Background and Definitions

    Background: Transplant recipients require immunosuppression that increases infection risk, while insufficient immunosuppression increases rejection risk; balancing these competing risks is a core clinical challenge.

    Immune function assays such as the ImmuKnow assay measure CD4+ T‑cell ATP production after mitogenic stimulation as a surrogate of global cellular immune function; the policy frames these assays as potential tools to risk‑stratify immunocompromised patients or to inform prophylaxis and monitoring decisions, but highlights that evidence is assay‑ and indication‑specific and frequently inconclusive.

    ImmuKnow Assay (Cylex) — FDA 510(k)-cleared whole-blood assay description
    FDA status (ImmuKnow/Cylex)FDA 510(k)-cleared whole-blood assay for detection of cell‑mediated immune response (cleared April 2002)
    Assay methodIncubates whole blood with phytohemagglutinin, immunoselects CD4 cells, lyses cells, and measures intracellular ATP via luciferin/luciferase luminescence (ng/ml)
    Intended useEstimate net cellular immune function to assist management of immunosuppressed patients
    ImmuKnow (CICFA) — assay measuring ATP production by CD4+ T cells after stimulation
    Analyte measuredATP production by CD4+ T cells after stimulation (measured in ng/ml)
    PrincipleMitogenic stimulation (PHA) → CD4 immunoselection → cell lysis → ATP detection by luciferin/luciferase luminescence
    Clinical interpretationUsed as surrogate of global cellular immune response; categorized into low/intermediate/high ranges in studies
    ATP threshold (example) — illustrative threshold noted in studies
    Illustrative ATP threshold example175 ng/ml cited as an optimal cutpoint to predict HCC recurrence in one liver transplant cohort
    CaveatThresholds vary by study and population; single time‑point values have limited diagnostic capacity
    RecommendationConsider serial monitoring and clinical context when interpreting thresholds
    Definition — FDA-cleared assay measuring CD4 T-cell ATP production after mitogenic stimulation
    Definition (ImmuKnow)FDA-cleared assay measuring CD4 T‑cell ATP production after mitogenic stimulation to estimate net immune system function
    Result unitsReported in ng/ml of intracellular ATP
    Clinical roleIntended to estimate global cellular immune response in immunosuppressed patients
    Pleximmune — FDA-authorized (HDE) assay measuring donor-specific alloreactive CD154+ T cells (pediatric liver/intestine)
    Pleximmune (definition/status)FDA-authorized (HDE) assay measuring donor-specific alloreactive CD154+ cytotoxic memory T cells; reported as an immunoreactivity index (IR)
    Intended populationPediatric liver and intestine transplant recipients
    Reported outputImmunoreactivity Index (IR) with pre- and post-transplant thresholds to predict rejection
    T-SPOT.CMV — ELISPOT-based lab test measuring CMV-specific T-cell responses; not FDA-cleared, performed in CLIA/CAP lab
    T‑SPOT.CMV descriptionELISPOT-based test measuring CMV-specific IFN-γ spots to pp65 and IE1 antigens; used to stratify CMV reactivation risk; performed in CLIA/CAP laboratory (not FDA-cleared)
    Clinical findingDual robust responses to IE1 and pp65 were associated with lower subsequent viremia in seropositive renal transplant recipients
    Monitoring useUsed serially post‑HCT to track recovery of CMV-specific immunity
    GcfDNA — graft-derived cell-free DNA definition
    Graft-derived cell-free DNA (GcfDNA)Circulating cell-free DNA originating from the graft; increased fraction may indicate allograft injury or rejection
    Measurement methodsQuantified by ddPCR, SNP‑panel sequencing, or targeted sequencing depending on assay
    Clinical implicationSubstantial increases often precede clinical/biochemical signs and may enable earlier intervention
    Donor-derived cell-free DNA definition and context
    Donor-derived cell-free DNA (dd-cfDNA)Cell-free DNA in recipient plasma that originates from the graft; elevated levels correlate with graft injury and rejection
    Reported thresholdsExamples include >1% (kidney SNP‑based assay), >=0.74% for AMR detection in one study, and 0.2% for heart surveillance
    Clinical useUsed as a noninvasive surveillance tool and in biopsy‑paired studies; performance varies by organ and assay
    CMV T Cell Immunity Panel (CMV-TCIP) — commercial assay measuring CMV-specific CD4+/CD8+ responses
    CMV T Cell Immunity Panel (CMV‑TCIP)Commercial panel measuring CMV‑specific CD4+ and CD8+ responses (intracellular IFN‑γ after antigen stimulation); not FDA-cleared for diagnostic use
    MethodWhole blood stimulation, intracellular cytokine staining, flow cytometry for CD4/CD8 IFN‑γ responses
    Clinical noteMay aid CMV risk stratification but lacks formal FDA clearance and large outcome studies
    IFN-γ ELISpot (T-Track CMV) — assay detecting interferon-gamma secreting cells after CMV antigen stimulation
    IFN-γ ELISpot (T‑Track CMV)Assay detecting interferon‑gamma secreting cells after stimulation with CMV antigens (pp65, IE1); evaluates CMV‑specific cellular immunity
    Assay considerationsResponses to proteins versus peptides may differ; concordance in one HSCT study was ~74.4%
    Use caseUsed to risk-stratify HSCT recipients for CMV reactivation and guide management decisions
    IFN-γ ELISpot — general definition
    IFN-γ ELISpot (general)Measures interferon‑gamma release from T cells after CMV antigen stimulation to evaluate CMV‑specific cellular immunity
    Clinical relevanceAbsence of adequate CMV‑specific T‑cell immunity correlates with higher risk of CMV disease across studies
    Laboratory statusOften performed as high‑complexity CLIA/CAP assays; not all platforms are FDA‑cleared
    QuantiFERON-CMV (QF-CMV) — IFN-γ release assay with reactive threshold
    QuantiFERON‑CMV (QF‑CMV)An IFN‑γ release assay using pre‑mixed CMV peptides to quantify CMV‑specific T‑cell responses; reactive threshold >=0.2 IU/mL
    Intended measurementPrimarily measures CD8+ (and some CD4+) T‑cell IFN‑γ response to CMV peptides
    Clinical utility caveatIndeterminate results and moderate inter‑assay agreement with ELISPOT limit interchangeability; assay‑specific validation recommended
    ImmuKnow — ATP-based assay categories referenced
    ImmuKnow — categorical interpretationReported categories include Low (<225 ng/mL), Intermediate (225–525 ng/mL), High (>=525 ng/mL)
    Clinical meaningLower ATP values generally associated with higher infection risk; higher values variably associated with rejection in some studies
    RecommendationUse categories with caution; consider serial trends and clinical context
    Immune cell function assays — list of assay types referenced in document
    Assays referenced in documentImmuKnow (ATP assay), Pleximmune (CD154+ TcM), T‑SPOT.CMV (ELISPOT), QuantiFERON‑CMV (IGRA), CMV‑TCIP, dd‑cfDNA/GcfDNA
    Assay purposesAssess global cellular immunity, donor‑specific alloreactivity, CMV‑specific immunity, or graft injury depending on assay
    Regulatory/validation noteSome assays FDA‑cleared/authorized (ImmuKnow 510(k), Pleximmune HDE), others are CLIA laboratory tests without FDA clearance

    Policy Revision History

    2009-01-09effective_date

    Policy became effective.

    2023-10-26policy_reviewLatest

    Most recent policy review conducted (Last Review: 10/26/2023).